(Q37273294)

19 August 2017

1 reference

title

Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises (English)

1 reference

19 August 2017

Jean E Sealey

1

1 reference

19 August 2017

John H Laragh

series ordinal

2

1 reference

19 August 2017

publication date

18 September 2008

1 reference

Journal of Clinical Hypertension

19 August 2017

published in

1 reference

19 August 2017

volume

22

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

112-121

1 reference

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

The captopril test for identifying renovascular disease in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Interpretation of plasma renin concentration in patients receiving aliskiren therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Plasma renin activity for predicting antihypertensive drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Renin and aldosterone suppression in the antihypertensive action of clonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

Laragh's lessons in pathophysiology and clinical pearls for treating hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Laragh's lessons in pathophysiology and clinical pearls for treating hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Laragh's lessons in pathophysiology and clinical pearls for treating hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Divergent blood pressure responses during short-term sodium restriction in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Neurohumoral and Metabolic Effects of Short-Term Dietary NaCl Restriction in Men Relationship to Salt-Sensitivity Status

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Detection of renovascular hypertension with angiotensin II blockade

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Prediction of salt sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Hypertension and chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Moderate sodium restriction. Do the benefits justify the hazards?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

A brief response to Sealey and Laragh

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Laragh's lessons in pathophysiology and clinical pearls for treating hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.275

7 January 2021

Identifiers

DOI

10.1038/AJH.2008.275

1 reference

19 August 2017

1 reference